Table 3.
Treatment-related adverse events.
| Adverse events | All grades, n (%) | Grade 3/4, n (%) | |
|---|---|---|---|
| Hypertension | 31 (27.2) | 10 (8.8) | |
| Hand-foot skin reaction | 17 (14.9) | 2 (1.8) | |
| Diarrhea | 14 (12.3) | 1 (0.9) | |
| Skin rash | 15 (13.2) | 2 (1.8) | |
| Proteinuria | 14 (12.3) | 4 (3.6) | |
| RCCEP | 5 (4.4) | 0 (0) | |
| Fatigue | 9 (7.9) | 1 (0.9) | |
| Epistaxis | 1 (0.9) | 0 (0) | |
| Joint pain | 6 (5.3) | 0 (0) | |
| Bleeding (gingiva) | 11 (9.6) | 2 (1.8) | |
| Dysphonia | 4 (3.6) | 0 (0) | |
| Anorexia | 6 (5.3) | 0 (0) | |
| Myocardial enzymes elevation | 14 (12.3) | 0 (0) | |
| Hypothyroidism | 39 (34.2) | 0 (0) | |
| AST elevation | 16 (14) | 4 (3.6) | |
| ALT elevation | 18 (15.8) | 2 (1.8) | |
| Hyperbilirubinemia | 14 (12.3) | 2 (1.8) | |
| Decreased albumin | 48 (42.1) | 0 (0) | |
| Decreased PLT | 42 (36.8) | 2 (1.8) | |
| Decreased WBC | 43 (37.7) | 5 (4.4) | |
| Interruption and/or dose reduction | 21 (18.4) | ||
| Discontinued PD-1 inhibitors | 2 (1.8) |
RCCEP, reactive cutaneous capillary endothelial proliferation; AST, aspartate aminotransferase; ALT, alanine aminotransferase, PLT, platelet; WBC white blood cell; PD-1 inhibitors, programmed death receptor-1 signaling inhibitors.